Market Overview

Analyst Updates 2020 GE Healthcare Projections Following Investor Day Event

Share:
Analyst Updates 2020 GE Healthcare Projections Following Investor Day Event

General Electric Company (NYSE: GE) held a GE Healthcare investor day event this week. One analyst in attendance said Tuesday that Healthcare should be a stable source of free cash flow for GE as it executes its turnaround strategy, but the GE bull case still hinges on Power.

The Analyst

Bank of America analyst Andrew Obin reiterated his Neutral rating and $12 price target for GE stock.

The Thesis

Obin listed three major takeaways from the event for investors:

  • Not including Biopharma, GE Healthcare should generate between $1.6 billion and $1.8 billion in free cash flow in 2020.
  • GE’s digital offerings have grown large enough to potentially help expand Healthcare margins.
  • There were no major surprises in GE’s Healthcare guidance of mid single-digit revenue growth and between 0.25% and 0.75% of margin expansion per year.

Including Biopharma, Obin projects $2.9 billion in 2020 free cash flow from GE Healthcare, down from $3 billion in 2018. He said Healthcare should be able to grow free cash flow in the high single digits starting in 2021.

“On balance, GE’s Power segment has more opportunity to drive either the Bull or Bear case,” Obin wrote in a note.

GE’s digital revenue is growing in the high single digits at margins of greater than 50%. Obin said the key risk to this growth is the potential for new competitor willing to sacrifice profits to gain market share.

Benzinga’s Take

The worst may finally be over for GE investors after years of market declines. However, GE will need to demonstrate it can generate sustainable cash flow and earnings growth to make the stock appealing to value investors.

GE's stock traded around $11 per share at time of publication.

Do you agree with this take? Email feedback@benzinga.com with your thoughts.

Related Links:

13 Stocks With The Highest Average Daily Trading Volume

Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

Photo credit: Momoneymoproblemz, via Wikimedia Commons

Latest Ratings for GE

DateFirmActionFromTo
Dec 2019UpgradesNeutralBuy
Dec 2019MaintainsHold
Sep 2019Initiates Coverage OnEqual-Weight

View More Analyst Ratings for GE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Reiteration Events Analyst Ratings General Best of Benzinga

 

Related Articles (GE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
SRPTPiperJaffrayMaintains210.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Day Market Update: Audentes Therapeutics Climbs On Acquisition News; ASLAN Pharmaceuticals Shares Slide

The Gene Therapy Names Moving On The Audentes Buyout Deal